Sign In
Buy IMUX
$13.97
-0.0200 (-0.143%)
At Close: Jul 31, 2026
– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Pr
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher
02:09am, Monday, 28'th Apr 2025
Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and rec
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
01:00pm, Thursday, 10'th Apr 2025
NEW YORK , April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ther
Immunic announces pricing of $5.1M direct offering to support clinical pipeline
08:53am, Wednesday, 09'th Apr 2025
Immunic Inc (NASDAQ:IMUX) has priced its $5.1 million registered direct offering led by Aberdeen Investments, selling 5.67 million shares at $0.90 each. The biotechnology company, which is advancing o
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
08:10am, Wednesday, 09'th Apr 2025
NEW YORK , April 9, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therap
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
06:30am, Tuesday, 01'st Apr 2025
NEW YORK , April 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflamm
Immunic provides MS research update – ICYMI
04:29pm, Friday, 14'th Mar 2025
Immunic Inc (NASDAQ:IMUX) earlier this week provided an update on its multiple sclerosis (MS) drug, vidofludimus calcium, highlighting its potential to address both inflammation and neuroprotection. D
Immunic to Participate in Scientific and Investor Conferences in March
06:30am, Monday, 03'rd Mar 2025
NEW YORK , March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflamma
Biotechs challenge big pharma with new oral weight loss therapies
11:44am, Friday, 28'th Feb 2025
With the smash success of glucagon-like peptide-1 (GLP-1) agonists as a treatment for obesity, pharmaceutical giants and emerging biotechnology firms alike are working to develop an equally effective
Immunic to highlight vidofludimus calcium's potential as MS therapy at upcoming forum
08:43am, Wednesday, 26'th Feb 2025
Immunic Inc (NASDAQ:IMUX) announced that it will present key data for its investigational drug vidofludimus calcium in two poster presentations at the Americas Committee for Treatment and Research in
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
06:30am, Wednesday, 26'th Feb 2025
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activation s in Preclinical Models – – Top-Line Data from Phase 2 C
Immunic drug candidate may offer new obesity treatment - ICYMI
08:41am, Saturday, 22'nd Feb 2025
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive to discuss the company's latest findings on IMU-856, a drug candidate initially studied for celiac disease. New data suggests that IMU-856
Immunic highlights IMU-856's potential as weight management therapy
10:02am, Thursday, 20'th Feb 2025
Immunic Inc (NASDAQ:IMUX) has released new data that supports the potential of its investigational therapeutic IMU-856 as an oral treatment for weight management. IMU-856, a small molecule that target
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Pos
Immunic to Participate in Investor and Scientific Conferences in February
06:30am, Tuesday, 04'th Feb 2025
NEW YORK , Feb. 4, 2025 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammato
